2,5-dimethyl-celecoxib, also known as DMC, is celecoxib analog that lacks COX-2 inhibitory activity but exhibits anti-tumor properties. DMC demonstrated its ability to inhibit xenograft tumor growth through the inhibition of Akt activation. The central mechanism for the anticancer effect of DMC is the suppression of the Wnt/β-catenin signaling pathway. DMS is a synthetic opener of KV7 channels in smooth muscle cells.